Transition pathway to support cancer patients after hospital discharge

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational feasibility study follows adults admitted to an oncology ward for at least 48 hours who are discharged home and able to use a connected device. Participants use electronic patient-reported outcome (ePRO) tools to report symptoms after discharge and receive follow-up contacts from clinical staff as part of the OncoCare transition program. The study will collect feasibility metrics alongside patient-reported outcomes, emergency department visits, and readmissions in the weeks after discharge. Results will inform whether this pathway can be scaled into routine oncology discharge care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The patient must have given their free and informed consent and signed the consent form
* The patient must be a member or beneficiary of a health insurance plan
* Adult patient hospitalized in an oncology unit for at least 48 hours.
* Patient capable of using a connected device, in possession of a smartphone or tablet, and with an internet connection at home.
* Patient discharged from hospital to go home.

Exclusion Criteria:

* The patient is in a period of exclusion determined by a previous study
* The subject refuses to sign the consent
* It is impossible to give the subject informed information
* The patient is under safeguard of justice or state guardianship
* Patient considered to be at the end of life.
* Patient unable to read and understand French
* Patient discharged from hospitalization to a home care facility
* Patient having been hospitalized in a full-time inpatient setting for a scheduled procedure (chemotherapy or interventional procedure)
* Pregnant, parturient, or breastfeeding

Where it's running

• Centre Hospitalier de Nimes
  Nîmes, France Recruiting

Study contacts

• Principal investigator: Astrid Basset — CHU de Nimes
• Study coordinator: Astrid Basset
• Email: astrid.basset@chu-nimes.fr
• Phone: 06.24.89.63.27

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Compare a new endoscopy-assisted breast-conserving surgery with the usual approach

  This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang and 21 other locations · NCT07920094

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.